Recently I have a group discussion about formulating a drug for Hepatocellular Carcinoma(HCC). My group agreed on using CRISPR/Cas 9 system to cure HCC, because theoretically it is more specific and less side effect than chemotherapy.

The problem lies in determining the oncogenes that the Cas 9 would cut. Should all the oncogenes be cut or only a few of them? Are there recent studies about this particular treatment? Lastly, because every patient mutation is unique does this effects which gene you should delete?

Oncogenes : Tp53 (32-36%), CTNNB1 (20-25%), AXIN1 (5-10%), IGF2R (18-33%), and hhcM

More Forbes Avila's questions See All
Similar questions and discussions